Cingulate
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Kansas, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1901 W 47th Pl, Kansas City, Kansas, 662...Phone Number
(913) 942-2300Website
www.cingulate.comRevenue
<$5 MillionStock Symbol
CINGIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Cingulate
Cingulate is a clinical stage biopharmaceutical company utilizing its proprietary Precision Timed Release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. Established in 2012, Cingulate is headquartered in Kansas City, Kansas, United States.Explore more
Cingulate Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cingulate your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Cingulate, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Cingulate
Check out if Cingulate is spiking on competitors!
Check if Cingulate has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Cingulate has new funding data
Click to see if Cingulate had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Cingulate recently announced quarterly report
Product Launch: Get notified when Cingulate launches new products
Recommended Actions
Find VP level buyers at Cingulate
Find 3 more new buyers
Compare Similar Companies to Cingulate
Compare insights from companies similar to Cingulate, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Cingulate is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Cingulate is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Cingulate.
Cingulate financials insights
Gather financial insights about Cingulate, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Private Equity
$6.8M
2018
Private Equity
$7.5M
2020
Debt
$150K
2021
Debt
$237K
2024
Share Placement
$5M
2025
Debt
$6.6M
Cingulate Tech Stack
A closer look at the technologies used by Cingulate
See more technologies
Most Recent Scoops
Earnings
Earnings, Finance
Earnings
Earnings, Finance
New Hire
Executive Move
Executive Moves, New Hire
Funding
Funding
Person-Based
Cingulate News & Media
Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301
Cash Position Grows to $25.9 Million Cash Position Grows to $25.9 MillionHere is Why Cingulate (CING) is One of the Best NASDAQ Growth Stocks to Buy and Hold Forever
Cingulate Inc. (NASDAQ:CING) is one of the best NASDAQ growth stocks to buy and hold forever. On March 18, Cingulate reported its financial results for Q4 and the full year 2025, highlighting the recent acceptance of an NDA for its lead ADHD candidate, CTx-1301. The company also announced a strengthened intellectual property portfolio, including a […]Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
U.S. Patent Notice of Allowance for CTx-1301 Received; Additional European Patents Granted Recent $12M Private Placement Closed At-the-Market Pricing U.S. Patent Notice of Allowance for CTx-1301 Received; Additional European Patents Granted Recent $12M Private Placement Closed At-the-Market PricingCingulate Announces the Closing of a $12 Million Private Placement Priced At-the-Market Under Nasdaq Rules
KANSAS CITY, Kan., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company advancing next-generation treatments for ADHD and other CNS disorders, today announced the successful closing of a $12 million private investment in public equity (PIPE) financing, led by certain affiliates of Falcon Creek Capital Advisor LLC (“Falcon Creek Capital”).
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Cingulate
Sign Up For FreeTo access detailed company insights
Cingulate is a clinical stage biopharmaceutical company utilizing its proprietary Precision Timed Release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and sub... Read More
